RealFeedApp Elena Ratti presents VY1706 and diranersen data at CTAD
Biogen is administering diranersen injections into cerebrospinal fluid, while Voyager Therapeutics presents two new antibodies at the CTAD conference in Boston.
- Field
- gene therapy
- What they did
- Voyager Therapeutics is preparing gene therapy for Alzheimer's disease to target the tau protein, which forms tangles inside brain cells.
- Why it matters
- Researchers hope that reducing this protein level will slow the disease, although it is currently unknown which method will work best.
#tau protein#alzheimer's disease#gene therapy#antibody#clinical trial
